Repurposing fusion inhibitor peptide against SARS‐CoV ‐2

2021 ◽  
Author(s):  
Faiyaz Md. Efaz ◽  
Shafiqul Islam ◽  
Shafi Ahmad Talukder ◽  
Shaila Akter ◽  
Md. Zakaria Tashrif ◽  
...  
Keyword(s):  
Fusion Inhibitor ◽  
Inhibitor Peptide

Half-life extension of the HIV-fusion inhibitor peptide TRI-1144 using a novel linker technology

2015 ◽  
Vol 93 ◽  
pp. 254-259 ◽  
Author(s):  
Eric L. Schneider ◽  
Gary W. Ashley ◽  
Lieve Dillen ◽  
Bart Stoops ◽  
Nigel E. Austin ◽  
...  
Keyword(s):  
Half Life ◽  
Life Extension ◽  
Fusion Inhibitor ◽  
Inhibitor Peptide

scholarly journals A Human DPP4-Knockin Mouse’s Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV

Viruses ◽  
2018 ◽  
Vol 10 (9) ◽  
pp. 448 ◽  
Author(s):  
Changfa Fan ◽  
Xi Wu ◽  
Qiang Liu ◽  
Qianqian Li ◽  
Susu Liu ◽  
...  
Keyword(s):  
Antiviral Agents ◽  
Respiratory Illness ◽  
Clinical Strain ◽  
Fusion Inhibitor ◽  
Dipeptidyl Peptidase 4 ◽  
Susceptibility To Infection ◽  
Inhibitor Peptide ◽  
Novel Model ◽  
Biosafety Level ◽  
Knockin Mouse

Infection by the Middle East respiratory syndrome coronavirus (MERS-CoV) causes respiratory illness and has a high mortality rate (~35%). The requirement for the virus to be manipulated in a biosafety level three (BSL-3) facility has impeded development of urgently-needed antiviral agents. Here, we established anovel mouse model by inserting human dipeptidyl peptidase 4 (hDPP4) into the Rosa26 locus using CRISPR/Cas9, resulting in global expression of the transgene in a genetically stable mouse line. The mice were highly susceptible to infection by MERS-CoV clinical strain hCoV-EMC, which induced severe diffuse pulmonary disease in the animals, and could also be infected by an optimized pseudotyped MERS-CoV. Administration of the neutralizing monoclonal antibodies, H111-1 and m336, as well as a fusion inhibitor peptide, HR2P-M2, protected mice from challenge with authentic and pseudotyped MERS-CoV. These results confirmed that the hDPP4-knockin mouse is a novel model for studies of MERS-CoV pathogenesis and anti-MERS-CoV antiviral agents in BSL-3 and BSL-2facilities, respectively.

In situ depot formation of anti-HIV fusion-inhibitor peptide in recombinant protein polymer hydrogel

2017 ◽  
Vol 64 ◽  
pp. 116-125 ◽  
Author(s):  
Daisuke Asai ◽  
Taisei Kanamoto ◽  
Mitsuko Takenaga ◽  
Hideki Nakashima
Keyword(s):  
Recombinant Protein ◽  
Fusion Inhibitor ◽  
Polymer Hydrogel ◽  
Protein Polymer ◽  
Inhibitor Peptide ◽  
Anti Hiv

Structure and conformation of HIV fusion inhibitor peptide T-1249 in presence of model membranes: A molecular dynamics study

2010 ◽  
Vol 946 (1-3) ◽  
pp. 119-124 ◽  
Author(s):  
A.M.T. Martins do Canto ◽  
A.J. Palace Carvalho ◽  
J.P. Prates Ramalho ◽  
Luís M.S. Loura
Keyword(s):  
Molecular Dynamics ◽  
Model Membranes ◽  
Fusion Inhibitor ◽  
Peptide T ◽  
Inhibitor Peptide

scholarly journals Lipid Vesicles Loaded with an HIV-1 Fusion Inhibitor Peptide as a Potential Microbicide

Pharmaceutics ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 502 ◽  
Author(s):  
Elena Sánchez-López ◽  
Anna Paús ◽  
Ignacio Pérez-Pomeda ◽  
Ana Calpena ◽  
Isabel Haro ◽  
...  
Keyword(s):  
Ex Vivo ◽  
Polymeric Nanoparticles ◽  
Entrapment Efficiency ◽  
Lipid Vesicles ◽  
Fusion Inhibitor ◽  
Vaginal Mucosa ◽  
Prolonged Release ◽  
Vaginal Tissue ◽  
Inhibitor Peptide ◽  
Hiv 1

The effective use of fusion inhibitor peptides against cervical and colorectal infections requires the development of sustained release formulations. In this work we comparatively study two different formulations based on polymeric nanoparticles and lipid vesicles to propose a suitable delivery nanosystem for releasing an HIV-1 fusion inhibitor peptide in vaginal mucosa. Polymeric nanoparticles of poly-d,l-lactic-co-glycolic acid (PLGA) and lipid large unilamellar vesicles loaded with the inhibitor peptide were prepared. Both formulations showed average sizes and polydispersity index values corresponding to monodisperse systems appropriate for vaginal permeation. High entrapment efficiency of the inhibitor peptide was achieved in lipid vesicles, which was probably due to the peptide’s hydrophobic nature. In addition, both nanocarriers remained stable after two weeks stored at 4 °C. While PLGA nanoparticles (NPs) did not show any delay in peptide release, lipid vesicles demonstrated favorably prolonged release of the peptide. Lipid vesicles were shown to improve the retention of the peptide on ex vivo vaginal tissue in a concentration sufficient to exert its pharmacological effect. Thus, the small size of lipid vesicles, their lipid-based composition as well as their ability to enhance peptide penetration on vaginal tissue led us to consider this formulation as a better nanosystem than polymeric nanoparticles for the sustained delivery of the HIV-1 fusion inhibitor peptide in vaginal tissues.

scholarly journals Combining 25-Hydroxycholesterol with an HIV Fusion Inhibitor Peptide: Interaction with Biomembrane Model Systems and Human Blood Cells

2019 ◽  
Vol 5 (4) ◽  
pp. 582-591 ◽  
Author(s):  
Bárbara Gomes ◽  
Giusepinna Sanna ◽  
Silvia Madeddu ◽  
Axel Hollmann ◽  
Nuno C. Santos
Keyword(s):  
Human Blood ◽  
Blood Cells ◽  
Model Systems ◽  
Fusion Inhibitor ◽  
Human Blood Cells ◽  
Inhibitor Peptide ◽  
Peptide Interaction

HIV Fusion Inhibitor Peptide T-1249 Is Able To Insert or Adsorb to Lipidic Bilayers. Putative Correlation with Improved Efficiency

2004 ◽  
Vol 126 (45) ◽  
pp. 14758-14763 ◽  
Author(s):  
A. Salomé Veiga ◽  
Nuno C. Santos ◽  
Luís M. S. Loura ◽  
Aleksandre Fedorov ◽  
Miguel A. R. B. Castanho
Keyword(s):  
Fusion Inhibitor ◽  
Peptide T ◽  
Inhibitor Peptide

Sifuvirtide, a potent HIV fusion inhibitor peptide

2009 ◽  
Vol 382 (3) ◽  
pp. 540-544 ◽  
Author(s):  
Rui-Rui Wang ◽  
Liu-Meng Yang ◽  
Yun-Hua Wang ◽  
Wei Pang ◽  
Siu-Cheung Tam ◽  
...  
Keyword(s):  
Fusion Inhibitor ◽  
Inhibitor Peptide
Sign in / Sign up

Export Citation Format

Share Document